Par Pharmaceutical Companies, Inc. f/k/a Par Pharmaceutical Holdings, Inc. | Search

Accessibility help Skip to navigation Skip to content Skip to footer

Showing results for Par Pharmaceutical Companies, Inc. f/k/a Par Pharmaceutical Holdings, Inc.

Sort by

Viewing results 1‒25 of 73

The Big Read
The inside story of the Pfizer vaccine: ‘a once-in-an-epoch windfall’
...Fatima Hassan, founder of South Africa’s Health Justice Initiative, says the health ministry was ill-equipped to negotiate with a “lawyered-up” pharmaceutical company like Pfizer....
November 30, 2021
The FT ViewThe editorial board
Vaccine protectionism by the EU will backfire
...There is a suspicion that pharmaceutical companies are using EU facilities to fulfil priority international orders while EU customers have to wait....
January 26, 2021
FT Live
Global Private Banking Awards 2024
Celebrating excellence in wealth management
Thursday, 7 NovemberThe Landmark London, London, UK
News in-depthCoronavirus treatment
How AstraZeneca and Oxford found their vaccine under fire
...“We can definitely say that the transparency from Oxford and AstraZeneca has not been on a par with what we have seen from the others,” said Rasmus Bech Hansen, chief executive of Airfinity, a London-based...
November 27, 2020
Due Diligence
Keeping up with the Kardashian deal machine Premium content
...Mark Crossley, Indivior’s chief financial and operations officer, will replace Shaun Thaxter as chief executive of the pharmaceutical company....
June 30, 2020
Technology sector
Big hedge fund bet on NXP hit by trade war
...Buried within bond contracts are clauses that have enabled some large companies to buy back debt issued to finance deals at par and thus not pay a premium....
July 20, 2018
Pharmaceuticals sector
Indivior warns of threat to key opioid addiction treatment after legal setback
...Watson Pharmaceuticals and Par Pharmaceutical have previously been prevented from working on a generic film alternative, but Indivior said the latest ruling means they “are now able to pursue their respective...
September 1, 2017
FT Live
US Pharma and Biotech Summit
Strategies for innovation, pricing and access
Thursday, 16 MayNew York, NY, USA
FT AlphavilleSiona Jenkins
Opening Quote: Indivior suffers legal setback on opioid treatment
...Watson Pharmaceuticals and Par Pharmaceutical have previously been prevented from working on a generic film alternative, but Indivior said the latest ruling means they “are now able to pursue their respective...
September 1, 2017
News in-depthUS & Canadian companies
MAmazon makes its move in healthcare
...have vested interests on a par with the Caribbean dictatorship....
January 31, 2018
Pharmaceuticals sector
Mylan drops as AGs look to expand generic drug-pricing lawsuit
...Reddy’s Laboratories, Inc.; Emcure Pharmaceuticals, Ltd.; Glenmark Pharmaceuticals, Inc.; Lannett Company, Inc.; Par Pharmaceutical Companies, Inc.; Sandoz, Inc.; Sun Pharmaceutical Industries,Inc.; and...
October 31, 2017
Banks
Mantra of Thailand’s oldest lender: go digital Premium content
...The company’s mobile banking app, SCB Easy, has roughly 6.5m users, while Kasikornbank’s K Plus boasts more than 8m. Both banks hope to reach 10m this year....
May 22, 2018
Cyber Security
Cyber attack hits global businesses and Ukraine government
...Mikko Hypponen, chief research officer at F-Secure, a Finnish cyber security company, could not confirm that attack came from the hackers who were behind WannaCry....
June 27, 2017
US equities
Drugmaker Endo rises on leadership change
...Mr Campanelli previously served as chief executive of Par Pharmaceutical and joined Endo after the company bought Par in 2015....
September 23, 2016
UK banks
Week in Review: January 28
...The company also helped to assuage investor fears over the margins of its newer growth businesses, by disclosing a commercial cloud gross margin of 48 per cent — on par with the previous quarter....
January 27, 2017
UK equities
Supermarkets in retreat on Asda war signal
...While generic drugmakers Actavis and Par are expected to appeal against the verdict, Indivior will now have at least another year to launch its successor treatment, a monthly injection, said Deutsche Bank...
June 3, 2016
High yield bonds
Healthcare junk bonds sting investors
...Dealmakers have struck $460bn in M&A transactions in healthcare since the year began, including Valeant’s $15.8bn deal for Salix, as well as Endo’s purchase of Par Pharmaceutical from TPG Capital and Mallinckrodt...
October 1, 2015
FT Live
Global Pharma and Biotech Summit
Driving life sciences innovation in a disrupted world
Tuesday, 5 NovemberIn-Person & Online Conference
LexUS & Canadian companies
Endo/Par: too much of a good thing
...Why, then, is the market so tepid on Endo’s $8bn cash and stock purchase of Par, a generics company? After Monday’s announcement, Endo’s shares fell 5 per cent....
May 18, 2015
US & Canadian companies
Endo to buy Par from TPG Capital in $8bn cash-and-shares deal
...The deal is the latest in a feverish game of brinkmanship being played out by some of the biggest companies in the pharmaceuticals sector....
May 18, 2015
US equities
Ann leaps after Ascena declares intentions
...The deal would help create a pharmaceutical company with a fast-growing generics business and it is also expected to drive long-term double-digit sales growth, according to Endo....
May 18, 2015
Pharmaceuticals sector
Australia’s CSL warns of biotech bubble
...This has coincided with a wave of M&A activity in the pharmaceutical and healthcare sector, including Shire’s US$30bn hostile takeover approach last week to US drugmaker Baxalta — a key competitor of CSL...
August 10, 2015
US & Canadian companies
Week in Review, March 21
...But by Thursday the company was forced into an embarrassing retraction, with Michael O’Leary apologising and saying Ryanair had “f****** up”....
March 20, 2015
US & Canadian companies
Week in Review, January 17
...He also predicted that his group would be selling “a few million” vehicles — on a par with BMW — by 2025, despit e a slowdown of sales in China....
January 16, 2015
Pharmaceuticals sector
Roche continues dealmaking with acquisition of Santaris
...Roche has taken a disciplined approach to making deal since the collapse in 2012 of a planned $6.8bn acquisition of Illumina, another US gene-sequencing company, and has not been drawn into the frenzy of...
August 4, 2014
US & Canadian companies
Activist hedge fund Elliott to push for Interpublic sale
...A battle to force the Swiss pharmaceutical group Actelion to sell itself in 2011 was defeated and Elliott sold its stake in the company....
July 24, 2014
Fund management
Aggressive tax avoidance troubles large investors
...This stuff can play havoc with share prices as we have seen in recent months with pharmaceutical companies on both sides of the Atlantic.”...
November 2, 2014
Mergers & Acquisitions
Shire jumps on renewed bid speculation
...If the rare-diseases business were a standalone company valued on par with US sector peers BioMarin and Alexion it could be worth $21bn-$25bn, more than three-quarters of Shire’s current market capitalisation...
April 22, 2014

Previous pagePage 1 of 3Next page